Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
To evaluate optimal usage of bevacizumab to compare which is better, continuing bevacizumab
and paclitaxel or switching to hormonal maintenance therapy followed by
bevacizumab+paclitaxel after induction therapy of bevacizumab+paclitaxel.
To examine biomarkers such as monitoring markers of study treatment as exploratory analysis.